These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
287 related articles for article (PubMed ID: 17683827)
1. Gemcitabine and cisplatin as neo-adjuvant chemotherapy for non-small cell lung cancer: a phase II study. Aydiner A; Kiyik M; Cikrikcioglu S; Kosar F; Gurses A; Turna A; Yazar A; Dilege S; Goksel T; Cakan A Lung Cancer; 2007 Nov; 58(2):246-52. PubMed ID: 17683827 [TBL] [Abstract][Full Text] [Related]
2. Decreased myelotoxicity of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) with cisplatin infusion on day 15. Cortesi E; Ramponi S; Corona M; Moscetti L; Grifalchi F; Oliva A; Lembo A; Gasperoni S; Padovani A Lung Cancer; 2001; 31(2-3):271-6. PubMed ID: 11165407 [TBL] [Abstract][Full Text] [Related]
3. Feasibility study for biweekly administration of cisplatin plus gemcitabine as adjuvant-chemotherapy for completely resected non-small cell lung cancer. Yamaguchi M; Takeo S; Suemitsu R; Matsuzawa H Cancer Chemother Pharmacol; 2010 May; 66(1):107-12. PubMed ID: 19809815 [TBL] [Abstract][Full Text] [Related]
4. Combination of gemcitabine and cisplatin for advanced non-small cell lung cancer: a phase II study with emphasis on scheduling. Huisman C; Giaccone G; van Groeningen CJ; Sutedja G; Postmus PE; Smit EF Lung Cancer; 2001; 33(2-3):267-75. PubMed ID: 11551422 [TBL] [Abstract][Full Text] [Related]
5. A phase II, open-label trial of bortezomib (VELCADE(®)) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer. Kontopodis E; Kotsakis A; Kentepozidis N; Syrigos K; Ziras N; Moutsos M; Filippa G; Mala A; Vamvakas L; Mavroudis D; Georgoulias V; Agelaki S Cancer Chemother Pharmacol; 2016 May; 77(5):949-56. PubMed ID: 26994909 [TBL] [Abstract][Full Text] [Related]
7. Gemcitabine and cisplatin treatment of advanced-stage non-small-cell lung cancer in patients given cisplatin on day 8. Akcali Z; Calikusu Z; Sakalli H; Ozyilkan O Tumori; 2008; 94(4):474-80. PubMed ID: 18822681 [TBL] [Abstract][Full Text] [Related]
9. A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer. Grossi F; de Marinis F; Gebbia V; Riccardi F; Caffo O; Gamucci T; Ferraù F; Nardi M; Moscetti L; Boni L; Dondi D; Galligioni E Cancer Chemother Pharmacol; 2012 Feb; 69(2):369-75. PubMed ID: 21833588 [TBL] [Abstract][Full Text] [Related]
10. Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial. Binder D; Schweisfurth H; Grah C; Schäper C; Temmesfeld-Wollbrück B; Siebert G; Suttorp N; Beinert T Cancer Chemother Pharmacol; 2007 Jun; 60(1):143-50. PubMed ID: 17031643 [TBL] [Abstract][Full Text] [Related]
11. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. Crinò L; Scagliotti G; Marangolo M; Figoli F; Clerici M; De Marinis F; Salvati F; Cruciani G; Dogliotti L; Pucci F; Paccagnella A; Adamo V; Altavilla G; Incoronato P; Trippetti M; Mosconi AM; Santucci A; Sorbolini S; Oliva C; Tonato M J Clin Oncol; 1997 Jan; 15(1):297-303. PubMed ID: 8996156 [TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy with gemcitabine and cisplatin in stage IIIA/B non-small cell lung cancer. Van Kooten M; Rosenberg M; Orlando M; Morero J; Vilanova M; Rojas O; Vicente H; Bagnes C; Silva C; Chacón RD Invest New Drugs; 2002 Nov; 20(4):439-46. PubMed ID: 12448663 [TBL] [Abstract][Full Text] [Related]
13. Gemcitabine combined with cisplatin as adjuvant chemotherapy for non-small cell lung cancer: A retrospective analysis. Ma D; Wang J; Hao X; Wang Y; Hu X; Xing P; Li J Thorac Cancer; 2017 Sep; 8(5):482-488. PubMed ID: 28745824 [TBL] [Abstract][Full Text] [Related]
14. The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group. Evans WK; Kocha W; Gagliardi A; Eady A; Newman TE Cancer Prev Control; 1999 Feb; 3(1):84-94. PubMed ID: 10474757 [TBL] [Abstract][Full Text] [Related]
15. A randomized study comparing two different schedules of administration of cisplatin in combination with gemcitabine in advanced nonsmall cell lung carcinoma. Ricci S; Antonuzzo A; Galli L; Tibaldi C; Bertuccelli M; Lopes Pegna A; Petruzzelli S; Bonifazi V; Orlandini C; Franco Conte P Cancer; 2000 Oct; 89(8):1714-9. PubMed ID: 11042565 [TBL] [Abstract][Full Text] [Related]
16. A randomized trial comparing adjuvant chemotherapy with gemcitabine plus cisplatin with docetaxel plus cisplatin in patients with completely resected non-small-cell lung cancer with quality of life as the primary objective. Barlesi F; Chouaid C; Crequit J; Le Caer H; Pujol JL; Legodec J; Vergnenegre A; Le Treut J; Fabre-Guillevin E; Loundou A; Auquier P; Simeoni MC; Thomas PA Interact Cardiovasc Thorac Surg; 2015 Jun; 20(6):783-90. PubMed ID: 25765952 [TBL] [Abstract][Full Text] [Related]
18. [Efficacy and toxicity of pemetrexed or gemcitabine combined with cisplatin in the treatment of patients with advanced non-small cell lung cancer]. Hu X; Jiao S; Zhang S; Wang Z; Wang M; Huang C; Zheng R; Li K; Wang J; Wang Y; Ouyang X; Lv W; Cheng G; Hu C; Luo R; Sun Y Zhongguo Fei Ai Za Zhi; 2012 Oct; 15(10):569-75. PubMed ID: 23075680 [TBL] [Abstract][Full Text] [Related]
19. Optimization of the schedule of gemcitabine-cisplatin combination as induction regimen for patients with biopsy-proven stage IIIa N2 - stage IIIb non-small-cell lung cancer: a prospective phase-II study. De Pas T; Curigliano G; Veronesi G; Catalano G; Catania C; Jereczek-Fossa B; Orecchia R; Spaggiari L; de Braud F Bull Cancer; 2004 Sep; 91(9):E273-7. PubMed ID: 15582897 [TBL] [Abstract][Full Text] [Related]
20. Gemcitabine, vinorelbine and cisplatin combination chemotherapy in advanced non-small cell lung cancer: a phase II trial. Laack E; Mende T; Dürk H; Kneba M; Dickgreber N; Welte T; Müller T; Scholtze J; Graeven U; Jasiewicz Y; Edler L; Hossfeld DK Eur J Cancer; 2002 Mar; 38(5):654-60. PubMed ID: 11916547 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]